U.S. patent number 3,723,524 [Application Number 05/036,461] was granted by the patent office on 1973-03-27 for polar-substituted propanolamines as anti-angina and anti-hypertensive agents.
This patent grant is currently assigned to Pfizer Inc.. Invention is credited to Joachim Augstein, Allan L. Ham, Peter R. Leeming, Michael Snarey.
United States Patent |
3,723,524 |
Augstein , et al. |
March 27, 1973 |
**Please see images for:
( Certificate of Correction ) ** |
POLAR-SUBSTITUTED PROPANOLAMINES AS ANTI-ANGINA AND
ANTI-HYPERTENSIVE AGENTS
Abstract
Novel propanolamine derivatives, especially
3-phenoxy-1-phenoxyalkylamino-2-propanols, useful in the treatment
of hypertension and cardiac conditions, such as angina pectoris and
cardiac arrhythmias.
Inventors: |
Augstein; Joachim (Linford,
EN), Ham; Allan L. (Leeming, EN), Leeming;
Peter R. (Kent, EN), Snarey; Michael (Kent,
EN) |
Assignee: |
Pfizer Inc. (New York,
NY)
|
Family
ID: |
26259405 |
Appl.
No.: |
05/036,461 |
Filed: |
May 11, 1970 |
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
877006 |
Nov 14, 1969 |
|
|
|
|
Foreign Application Priority Data
|
|
|
|
|
Nov 18, 1968 [GB] |
|
|
54,534/68 |
Jun 5, 1969 [GB] |
|
|
24,492/69 |
|
Current U.S.
Class: |
564/165; 544/137;
544/168; 546/209; 546/224; 546/232; 548/539; 548/557; 549/560;
552/10; 558/58; 560/10; 560/18; 562/451; 564/86; 564/150; 568/45;
568/649; 544/159; 544/169; 546/223; 546/226; 548/215; 548/540;
548/542; 549/559; 552/8; 558/44; 558/61; 560/12; 560/42; 564/81;
564/99; 564/349; 568/55; 568/643 |
Current CPC
Class: |
C07C
243/38 (20130101); C07D 263/04 (20130101); C07C
247/00 (20130101); C07D 263/06 (20130101) |
Current International
Class: |
C07C
243/00 (20060101); C07D 263/00 (20060101); C07D
263/04 (20060101); C07D 263/06 (20060101); C07C
243/38 (20060101); C07c 103/28 () |
Field of
Search: |
;260/559S,559A,559H,37F |
References Cited
[Referenced By]
U.S. Patent Documents
Other References
Levy: Proc. Soc. Exptl. Bio. Med. Vol. 122:378 (1966). .
Somani: C.A. Vol. 70: 66535e (April 1969)..
|
Primary Examiner: Jiles; Henry R.
Assistant Examiner: Winters; S. D.
Parent Case Text
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part application of U.S. Ser.
Number 877,006, filed on Nov. 14, 1969 under Group 126, and now
abandoned.
Claims
What is claimed is:
1. A compound selected from the group of propanolamines consisting
of those of the formula:
the pharmaceutically-acceptable acid addition salts thereof; the
carboxylic acid esters of the formula:
wherein R.sup.12 is selected from the group consisting of formyl,
lower alkanoyl, lower alkenoyl, and benzoyl; and the aldehyde
condensation products of the formula:
wherein R.sup.8 is selected from the group consisting of hydrogen
and lower alkyl; R.sup.1 is selected from the group consisting of
hydrogen, halogen, lower alkyl, lower alkoxy, phenyl, and
phenyl-substituted lower alkyl; R.sup.2 and R.sup.7 are each
selected from the group consisting of hydrogen, halogen, lower
alkyl, and lower alkoxy; R.sup.3 is an electron-withdrawing polar
substituent selected from the group consisting of CONR.sup.9
R.sup.10 and CONHNR.sup.9 R.sup.10, where R.sup.9 and R.sup.10 are
each hydrogen or lower alkyl;
R.sup.4, r.sup.5, and R.sup.6 are each selected from the group
consisting of hydrogen and lower alkyl;
and n is 1, 2, or 3.
2. A compound as claimed in claim 1 in which R.sup.4 is hydrogen or
a methyl group, R.sup.5 is hydrogen, and n is 1.
3. A compound as claimed in claim 2 in which R.sup.2 is hydrogen,
chlorine, methyl, or methoxy.
4. A compound as claimed in claim 2, in which R.sup.3 is in the 2-
or 4-ring position.
5. A compound as claimed in claim 4, in which R.sup.1 is methyl,
methoxy, or phenyl on the 2-ring position, and R.sup.3 is
CONH.sub.2 in the 2- or 4-ring position, provided that when R.sup.3
is in the 2-position then R.sup.2 is methyl or methoxy in the 4-,
5- or 6-ring position.
6.
1-[2-(4-carbamoylphenoxy)ethylamino]-3-(2-methyl-phenoxy)propan-2-ol.
7.
1-[2-(4-carbamoylphenoxy)ethylamino]-3-(2-methoxy-phenoxy)propan-2-ol.
8.
1-[2-(2-carbamoyl-4-methylphenoxy)ethylamino]-3-(2-methylphenoxy)propan-
2-ol.
9. 1-
[2-(2-carbamoyl-4-methylphenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy)pr
opan-2-ol.
10. 1[2-(2
-carbamoyl-4-methoxyphenoxy)-1-methyl-ethyl-amino]-3-(2-methylphenoxy)propa
n-2-ol.
11. 1-[
2-(2-carbamoyl-6-methylphenoxy)-1-methyl-ethyl-amino]-3-(2-methylphenoxy)pr
opan-2-ol.
12. 1-[2-(
4-carbamoylphenoxy)-1-methyl-ethylamino]-3-(2-phenylphenoxy)propan-2-ol.
Description
BACKGROUND OF THE INVENTION
This invention relates to novel propanolamine derivatives, which
have useful therapeutic properties in the field of medicinal
chemistry, and is particularly concerned with
3-phenoxy-1-phenoxyalkylamino-2-propanols, in which the phenyl
group of the 1-substituent carries an electron-withdrawing polar
substituent, and analagous compounds in which one or other of the
phenyl groups is replaced by a naphthyl group. More particularly
the compounds of the invention are useful in the curative or
prophylactic treatment of cardiac conditions, such as angina
pectoris and cardiac arrhythmias, and in the treatment of
hypertension. Angina pectoris and cardiac arrhythmias (irregular
heart beat) are due to interference with the blood supply to the
heart muscle. In the past, drugs have been sought which would
improve the blood supply and most work has concentrated on attempts
to dilate the coronary arteries. More recently, efforts have been
made to find drugs which will block the .beta.-adrenergic receptors
in heart muscle and thus prevent over stimulation of the heart.
The heart muscle is directly influenced by nervous system stimuli
substances or catecholamines (e.g. adrenaline, non-adrenaline, and
isoprenaline) which affect body organs such as the heart by
attaching themselves to "receptors" which are specialized areas of
the cell membranes. Particularly, the .beta.-adrenergic receptors
are concerned in the stimulation of heart muscle, and the compounds
of this invention exhibit a tendency to block .beta.-adrenergic
receptors and reduce the effect of the nervous system
catecholamines on the heart.
SUMMARY OF THE INVENTION
The compounds of the invention are those having the general
formula:
where:
R.sup.1 represents hydrogen, halogen or a lower alkyl, lower
alkoxy, phenyl, or phenyl-substituted lower alkyl group;
R.sup.2 and R.sup.7 each represent hydrogen, halogen or a lower
alkyl or alkoxy group;
R.sup.3 represents carboxy, lower alkoxycarbonyl, formyl, lower
alkanoyl, sulfo, sulfino, lower alkoxysulfonyl, lower
alkoxysulfinyl, cyano, azido, nitro, trifluoromethyl, CONR.sup.9
R.sup.10, SO.sub.2 NR.sup.9 R.sup.10, CONHNR.sup.9 R.sup.10, and
SO.sub.2 NHNR.sup.9 R.sup.10, where R.sup.9 and R.sup.10 are each
hydrogen, lower alkyl, or phenyl, or taken together with the
nitrogen atom to which they are attached complete a heterocyclic
group, e.g. a pyrrolidino, piperidino, piperazino, or morpholino
group;
R.sup.4 and R.sup.5 each represent hydrogen or a lower alkyl
group;
R.sup.6 represents hydrogen or a lower alkyl, lower alkanoyl or
benzyl group;
rings A and B may each be phenyl or naphthyl;
X represents oxygen or sulfur;
Y represents oxygen, sulfur, or a sulfinyl, sulfonyl, or
N(R.sup.11) wherein R.sup.11 represents hydrogen or lower
alkyl;
m is 0 or 1;
n is 1, 2, or 3 when m is 1; n is 0, 1, 2, 3, or 4 when m is 0;
and K is 0, 1, or 2;
the carboxylic acid esters and aldehyde condensation products of
such compounds, and their pharmaceutically acceptable acid addition
salts.
The novel compounds of the invention are useful as anti-angina and
anti-hypertensive agents in mammals. Particularly effective
compounds are those belonging to the class of
3-phenoxy-1-phenoxyalkylamino-2-propanols. Even more particularly
effective are the compounds of the class previously mentioned in
which the polar substituent is a carbamoyl group.
DETAILED DESCRIPTION OF THE INVENTION
In this specification "halogen" comprises fluorine, chlorine,
bromine and iodine; and the term "lower," used to qualify an alkyl
(R), alkoxy (OR), or alkanoyl (RCO) group, indicates that within
such group R contains up to 4 carbon atoms.
The aldehyde condensation products of the compounds of the
invention are oxazolidines, having the formula: ##SPC1##
which are formed by condensation of compounds of the invention in
which R.sup.6 is hydrogen with an aldehyde of the formula R.sup.8
CHO, where R.sup.8 is hydrogen or a lower alkyl group.
The compounds of the invention, which includes optically-active
isomers, have the property of blocking the .beta.-adrenergic
receptors and are useful in the curative or prophylactic treatment
of cardiac conditions, such as angina pectoris and cardiac
arrhythmias, and in the treatment of hypertension. Particularly
effective compounds of the invention are those of the class of
3-phenoxy-1-phenoxyalkylamino-2-propanols. More particularly are
those in which the polar substituent is a carbamoyl group such as,
1-[2-(4-carbamoylphenoxy)ethylamino]-3-(2-methylphenoxy)propan-2-ol;
1-[2-(4-carbamoylphenoxy)ethylamino]-3-(2-methoxyphenoxy)propan-2-ol;
1-[2-(2-carbamoyl-4-methylphenoxy)ethylamino]-3-(2-methylphenoxy)
propan-2-ol;
1-[2-(2-carbamoyl-4-methylphenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy
)propan-2-ol;
1-[2-(2-carbamoyl-4-methoxyphenoxy)-1-methyl-ethylamino]-3-(2-methylphenox
y)propan-2-ol;
1-[2-(2-carbamoyl-6-methylphenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy
)propan-2-ol;
1-[2-(4-carbamoylphenoxy)-1-methylethylamino]-3-(2-phenylphenoxy)propan-2-
ol; and
1-[2-(4-methoxycarbonyl-2,6-dimethylphenoxy)-1-methyl-ethylamino]-3-(2-met
hylphenoxy)propan-2-ol.
Electron-withdrawing polar substituents are those which contain a
polar group with its electropositive atom either adjacent to the
phenyl or naphthyl ring or separated from the phenyl or naphthyl
ring by a methylene or ethylene group. Such polar groups include
carbonyl, sulfonyl, sulfinyl, cyano, azido, nitro, trihalomethyl
groups.
Thus R.sup.3 in the above formula may be carboxy, lower
alkoxycarbonyl, formyl, lower alkanoyl, substituted carbamoyl,
N-amino-carbamoyl, sulfo, sulfino, alkoxysulfonyl, alkoxysulfinyl,
substituted sulfamoyl, N-amino-sulfamoyl, cyano, azido, nitro, or
trifluoromethyl group. This, of course, does not exclude other
electron-withdrawing polar substituents which are contemplated by
this invention.
Substituted carbamoyl and sulfamoyl groups and their N-amino
derivatives are those having the formulas --CO. NR.sup.9 R.sup.10,
--SO.sub.2. NR.sup.9 R.sup.10, --CO.NHNR.sup.9 R.sup.10, and
--SO.sub.2 NHNR.sup.9 R.sup.10, respectively, where R.sup.9 and
R.sup.10 are each hydrogen or a lower alkyl or a phenyl group, or
together with the nitrogen atom to which they are attached complete
a hetero-cyclic group, e.g. a pyrrolidino, piperidino, piperazino
or morpholino group.
The compounds of the invention may be prepared in a number of ways:
(1) A compound of the formula
where Z is halogen or any other suitable "leaving" group, e.g. a
sulfonyloxy group such as C.sub.6 H.sub.5.SO.sub.2.O-- or
p--CH.sub.3.C.sub.6 H.sub.4.SO.sub.2.0-, may be reacted with an
amine of the formula
where R.sup.6 is hydrogen, lower alkyl, or benzyl, by heating,
either in the presence of excess amine and a suitable solvent, e.g.
methanol, or in equimolar proportions in the presence of an alkali
such as sodium bicarbonate. After filtration and evaporation to
dryness the product is recovered by distillation in vacuo or by
dissolving in a suitable solvent and precipitating as a suitable
salt, e.g. the hydrochloride, maleate, fumarate or oxalate, by
addition of the appropriate acid. (2) An amine of the formula
where R.sup.6 is hydrogen, lower alkyl, or benzyl, may be reacted
with a compound of the formula
and the product recovered, the conditions for reaction and recovery
being similar to those given for method (1). (3) An epoxy compound
of the formula
may be reacted with an amine of the formula
where R.sup.6 is hydrogen, lower alkyl, or benzyl, in equimolar
proportions at ambient temperature, and the product recovered as in
methods (1) and (2). (4) An amine of the formula
may be reacted with an aldehyde or ketone of the formula
to give the corresponding Schiff's base, which is reduced in the
presence of a catalyst, e.g. platinum, to a compound of the
invention in which R.sup.5 and R.sup.6 are each hydrogen. This
method is preferred where R.sup.4 is lower alkyl.
The aldehyde condensation products of the compounds of the
invention may be prepared by reacting a compound of the invention
in which R.sup.6 is hydrogen with an aldehyde of the formula
R.sup.8 CHO, where R.sup.8 is lower alkyl, in a diluent or solvent,
e.g. ethanol, preferably in the presence of an acid catalyst, e.g.
hydrochloric or acetic acid, and preferably at an elevated
temperature. The water formed in the reaction may be removed by
azeotropic distillation by means of an entraining solvent, e.g.
benzene, or by a dehydrating agent such as anhydrous potassium
carbonate.
Esters of compounds of the invention, and compounds in which
R.sup.6 is lower alkanoyl, may be formed by acylation of the free
hydroxyl group or the secondary amino group, respectively, in a
conventional manner with a carboxylic acid chloride or anhydride
derived from a saturated or unsaturated aliphatic acid or from an
aromatic acid (e.g. acetic anhydride or benzoyl chloride) for the
esters, or with a lower alkanoic acid chloride or anhydride for
introduction of R.sup.6.
The compounds of the invention exist in D- and L-opticallyactive
isomeric forms and the invention includes these forms as well as
the racemic mixtures. Methods of preparation (1), (2) and (4)
described previously may be used to prepare opticallyactive isomers
by using the appropriate substituted 2-propanol enantiomer as
starting material, whereas method (3) will result in the production
of racemic mixtures. Alternatively, the racemic product of any of
the above methods may be resolved by well known techniques, e.g. by
fractional crystallization of an addition salt formed with an
optically active acid.
Compounds of the invention in which R.sup.4 is not the same as
R.sup.5 have two asymmetric centers and exist as two racemic pairs
of diastereoisomers. In general, the products of each of the
methods (1) to (4) described above, when R.sup.4 is not the same as
R.sup.5, will be a mixture of the two pairs of steroisomers, and
these pairs may usually be separated from each other by physical
methods, e.g. by fractional crystallization or chromatography of
the free bases or suitable salts, as shown in Examples XIII and
XLVII . The invention includes the separated pairs, as well as
mixtures thereof, as racemic mixtures or as separated D- and L-
forms.
Acids from which pharmaceutically acceptable addition salts of the
compounds of the invention can be prepared are those which form
non-toxic acid addition salts containing pharmaceutically
acceptable anions, such as the hydrochloride, hydrobromide,
hydroiodide, sulphate or bisulphate, phosphate or acid phosphate,
acetate, maleate, fumarate, lactate, tartrate, citrate, gluconate,
saccharate and p-toluene sulfonate salts.
The compounds of the invention can be administered alone, but will
generally be administered in admixture with a pharmaceutical
carrier selected with regard to the intended route of
administration and standard pharmaceutical practice. For example,
they may be administered orally, preferentially in the form of
tablets containing such excipients as starch or lactose, or in
capsules either alone or in admixture with excipients, or in the
form of elixirs or suspensions containing flavoring or coloring
agents. They may be injected parenterally, for example,
intramuscularly or subcutaneously. For parenteral administration,
they are best used in the form of a sterile aqueous solution which
may contain other solutes, for example, enough salts or glucose to
make the solution isotonic.
The starting materials necessary for the above reaction methods
leading to the desired compounds are either all known compounds or
else they can easily be prepared by those skilled in the art in
accordance with standard organic procedures.
Among these compounds, a preferred class of compounds has been
found to be those in which R.sup.4 is hydrogen or a methyl group,
R.sup.5 is hydrogen, Y is oxygen and n is 1. More particularly,
there are preferred those compounds in which R.sup.2 is hydrogen,
methyl, methoxy (R.sup.7 being hydrogen or methoxy when R.sup.2 is
methoxy) or chloro, R.sup.3 is an unsubstituted carbamoyl group,
and K is 0 or 1. Preferably, the unsubstituted carbamoyl group is
attached to a phenyl ring in the 2-position or the 4-position, and
when it is in the 2-position then preferably R.sup.2 is methyl or
methoxy in the 4-, 5-, or 6-position.
Compounds of the invention may be prepared in a number of ways as
described previously, but the preferred method for preparation of
compounds in which R.sup.4 is lower alkyl and R.sup.5 is hydrogen
is that in which an amine of the formula
is reacted with a ketone of the formula
to give the corresponding Schiff's base, which is reduced with
hydrogen in the presence of a catalyst, e.g. platinum, or with
sodium borohydride, to a compound of the invention in which R.sup.5
and R.sup.6 are each hydrogen.
The invention is illustrated by the following Examples in which
temperatures are given as .degree.C.
EXAMPLE I
2-(2-Bromoethoxy)benzamide (12.2g.),
DL-1-amino-3-(2-methylphenoxy)propan-2-ol (9 g.), sodium
bicarbonate (4.2 g.) and ethanol (100 ml.) were refluxed together
for 16 hr. The mixture was cooled, filtered and evaporated in vacuo
to give a semi-solid residue. The residue was stirred with benzene
(60 ml.) and the insoluble material was removed by filtration.
Evaporation of the benzene liquors gave a gum which was redissolved
in ethanol and converted to an oxalate by treatment with ethereal
oxalic acid solution. The oxalate was recrystallized from aqueous
ethanol as white needles m.p. 121.degree.C. Basification of the
oxalate gave the free base of
DL-1-[2-(2-carbamoylphenoxy)ethylamino]-3-(2-methylphenoxy)propan-2-ol
(2 g.) as a white solid, m.p. 105.5.degree.-106.degree.C.
Analysis found: C, 66.4; H, 6.9; N, 8.0%
Calc'd for: C.sub.19 H.sub.24 N.sub.2 O.sub.4 : C, 66.25; H, 7.0;
N, 8.1%
EXAMPLE II
2-(3-Chloropropoxy)benzamide (19.4 g.),
DL-1-amino-3-(2-methylphenoxy)propan-2-ol (16.4 g.), sodium
bicarbonate (11.4 g.) and ethanol (200 ml.) were refluxed together
for 16 hr. The mixture was cooled and filtered to remove inorganic
material. The ethanolic liquors were evaporated in vacuo to give
the crude product as a sticky solid (35.5 g.). Recrystallization
from ethanol gave two crops which differed in physical properties.
The second crop (10.3 g.) was recrystallized from isopropanol to
give
DL-1-[3-(2-carbamoyl-phenoxy)propylamino]-3-(2-methylphenoxy)propan-2-ol
as a white crystalline solid (8 g.) m.p.
117.degree.-118.degree.C.
Analysis - found: C, 66.95; H, 7.5; N, 7.7%
Calc'd for C.sub.20 H.sub.26 N.sub.2 O.sub.4 : C, 67.0; H, 7.3; N,
7.8%
EXAMPLE III
A mixture of 2-carbamoyl-phenoxy-acetone (19 g.)
DL-1-amino-3-(2-methylphenoxy)propan-2-ol (18.1g.) and ethanol (250
ml.) was treated with platinum oxide (100 mg.) and hydrogenated at
a pressure of 60 p.s.i. and 50.degree.C. for 12 hours. The catalyst
was removed by filtration followed by evaporation to dryness in
vacuo. The oily residue was converted to the oxalate and dissolved
in a boiling mixture of ethanol and water. On cooling, the oxalate
of unchanged starting material was deposited and removed by
filtration. The ethanolic liquors were evaporated to dryness and
basified with sodium carbonate to give
DL-1-[2-(2-carbamoylphenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy)propa
n2-ol as the free base, which after extraction into chloroform,
followed by drying and evaporation, was obtained as an oily solid.
Recrystallization from ethyl acetate gave the product as a white
solid (2 g.) m.p. 131.degree.-4.degree.C.
Analysis - found: C, 67.4; H, 7.55; N, 7.6%
Calc'd for C.sub.20 H.sub.26 N.sub.2 O.sub.4 : C, 67.0; H, 7.3; N,
7.8%
EXAMPLE IV
1-(2-Methylphenoxy)-2:3 -epoxypropane (6 g.) and
N-(4-ethoxycarbonylphenyl)ethylene diamine (5 g.) were heated
together in ethanol (20 ml.) for 2 hrs., followed by standing at
room temperature for 16 hours. The ethanol was evaporated in vacuo
and the residue was dissolved in ether. The oxalate was
precipitated by the addition of ethereal oxalic acid and after two
recrystallizations (ethanolwater)
DL-N-(4-ethoxycarbonylphenyl)-N'-[3-(2-methylphenoxy)-2-hydroxypropyl]
ethylenediamine oxalate was obtained as a white crystalline solid
(2.2 g.) m.p. 161.5.degree.-162.5.degree.C.
Analysis - found: C, 59.9; H, 6.5; N, 6.0
Calc'd for C.sub.23 H.sub.30 N.sub.2 O.sub.8 : C, 59.7; H, 6.5; N,
6.1%
EXAMPLE V
1-(4-Dimethylsulfamoylphenoxy)-2-bromethane (6 g.),
DL-3-(2-methylphenoxy)-1-aminopropan-2-ol (5 g.) and sodium
bicarbonate (1.6 g.) were refluxed together in absolute ethanol
(100 ml.) for 16 hours. After cooling the mixture was filtered and
evaporated to dryness in vacuo. The residue was dissolved in ether
and converted to the oxalate by treatment with ethereal oxalic acid
solution. The oxalate was recrystallized from water and
DL-1-[2-(4-dimethylsulfamoylphenoxy)ethylamino]-3-(2-methylphenoxy)propan-
2-ol oxalate was obtained as a white crystalline solid (1.6 g.)
m.p. 182.degree.-183.5.degree.C.
Analysis - found: C, 52.3; H, 5.9; N, 5.75; S, 6.5%
Calc'd for C.sub.22 H.sub.30 N.sub.2 O.sub.9 S: C, 53.0; H, 6.1; N,
5.6; S, 6.4%
The following compounds were prepared by the methods of Examples I
or II, from the appropriate (halo-alkoxy) benzene derivative and
DL-1-amino-3-phenoxy-propan-2-ol derivative, as indicated:
##SPC2##
The products, isolated as the free base in each case unless
otherwise stated, were characterized as follows, calculated
analytical figures being given in brackets below the found values
in each case:
Analysis % Example m.pt. C H N
__________________________________________________________________________
VI 100-102.degree. 62.38 6.35 7.92 (62.41 6.46 8.09)
157-159.degree. 66.2 7.0 7.8 (66.25 7.0 8.1) VIII 103-104.degree.
66.7 7.3 7.8 (67.0 7.3 7.8) IX 187-190.degree. 57.1 6.3 6.2
(oxalate) (56.9 6.1 6.0) X(A) 178-181.degree. 58.9 6.6 6.5
(oxalate) (58.9 6.3 6.3) X(B) 129-130.degree. 66.7 7.4 7.7 (67.0
7.3 7.8) X(C) 108-110.degree. 64.0 6.6 7.4 (64.2 7.0 7.5) X(D)
115-118.degree. 66.9 7.1 7.9 (67.0 7.3 7.8) X(E) 234-238.degree.
54.2 5.6 7.1 (hydrochloride) (53.9 5.5 7.0) X(F) 138-9.degree. 71.1
6.7 6.5 (71.4 6.7 6.7) X(G) 118-119.degree. 66.7 7.2 7.6 (67.0 7.3
7.8) X(H) 191-195.degree. 59.8 6.4 6.9 (hydrochloride) (59.9 6.6
7.4) X(I) 155-156.degree. 62.0 6.9 6.6 (62.4 7.0 6.9) X(J)
96-98.degree. 67.1 7.4 7.7 67.0 7.3 7.8) X(K) 124-127.degree. 59.9
6.7 5.8 (oxalate) (59.7 6.5 6.1) X(L) 181-184.degree. 58.3 6.4 6.1
(oxalate) (58.9 6.3 6.3)
__________________________________________________________________________
EXAMPLE XI
1-[2-(2-carbamoyl-4-methylphenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy)
propan-2-ol
2-Carbamoyl-4-methylphenoxyacetone (5 g.) and
DL-1-amino-3-(2-methylphenoxy)propan-2-ol (4 g.) were refluxed in
ethanol for 1 hour. The ethanol was removed in vacuo and replaced
with methanol (50 ml.) followed by the slow addition of sodium
borohydride (2 g.) at 25.degree.-30.degree.. The mixture was
stirred for 30 minutes and then poured onto ice and acidified with
acetic acid. Rebasification with sodium carbonate was followed by
extraction with chloroform. The extract was dried over magnesium
sulfate and evaporated in vacuo to give an oil which solidified on
standing. Recrystallization from a mixture of ethanol and water
gave the pure free base (3.5 g.) m.p.
110.5.degree.-113.degree..
Analysis: Found - C, 67.23; H, 7.36; N, 6.99% C, 66.65; H, 7.16; N,
7.21%
Calc'd for: C.sub.21 H.sub.28 N.sub.2 O.sub.4 - C, 67.72; H, 7.58;
N, 7.52%
The following compounds were prepared by the method of Example XI ,
from DL-1-amino-3-(2-methylphenoxy)propan-2-ol and the appropriate
ketone, as indicated:
Example R.sup.2 R.sup.3 R.sup.4 ketone
__________________________________________________________________________
XII 5-CH.sub.3 3-CONH.sub.2 CH.sub.3
3-carbamoyl-5-methylphenoxyacetone XIII 4-Cl 2-CONH.sub.2 CH.sub.3
2-carbamoyl-4-chlorophenoxyacetone XIV H 4-CONH.sub.2 CH.sub.3
4-carbamoylphenoxyacetone XV 5-CH.sub.3 2-CONH.sub.2 CH.sub.3
2-carbamoyl-5-methylphenoxyacetone XVI H 3-CONH.sub.2 CH.sub.3
3-carbamoylphenoxyacetone XVII H 3-CON(CH.sub.3).sub.2 CH.sub.3
3-dimethylcarbamoylphenoxyacetone XVIII H 2-CONH.sub.2 C.sub.2
H.sub.5 1-(2-carbamoylphenoxy)butan-2-one XIX H 4-NO.sub.2 CH.sub.3
4-nitrophenoxyacetone XX H 4-COOCH.sub.3 CH.sub.3
4-methoxycarbonylphenoxyacetone XXI H 4-CN CH.sub.3
4-cyanophenoxyacetone XXII H 3-CF.sub.3 CH.sub.3
3-trifluoromethylphenoxyacetone XXIII H 4-CH.sub.2 CONH.sub.2
CH.sub.3 4-carbamoylmethylphenoxyacetone XXIV H 2-CH.sub.2
CONH.sub.2 CH.sub.3 2-carbamoylmethylphenoxyacetone XXV H
2-CONHC.sub.6 H.sub.5 CH.sub.3 2-(N-phenylcarbamoyl)phenoxyaceton e
XXVI 2-OCH.sub.3 5-CONH.sub.2 CH.sub.3
5-carbamoyl-2-methoxyphenoxyaceton e XXVIII 4-CH.sub.3
2-CON(CH.sub.3).sub.2 CH.sub.3 2-(N,N-dimethylcarbamoyl)-4-methyl
phenoxyacetone XXIX 3-CH.sub.3 4-CONH.sub.2 CH.sub.3
4-carbamoyl-3-methylphenoxyacetone XXX H 4-SO.sub.2 NH.sub.2
CH.sub.3 4-sulfamoyl-phenoxyacetone XXXI 2-OCH.sub.3 4-CONH.sub.2
CH.sub.3 4-carbamoyl-2-methoxyphenoxyaceton e XXXII 4-OCH.sub.3
2-CONH.sub.2 CH.sub.3 2-carbamoyl-4-methoxyphenoxyaceton e XXXIII
2-CH.sub.3 4-CONH.sub.2 CH.sub.3 4-carbamoyl-2-methylphenoxyacetone
XXXIV 3-CH.sub.3 4-NO.sub.2 CH.sub.3 3-methyl-4-nitrophenoxyacetone
XXXVI 2-CH.sub.3 5-CONH.sub.2 CH.sub.3
5-carbamoyl-2-methylphenoxyacetone XXXVII 6-CH.sub.3 2-CONH.sub.2
CH.sub.3 2-carbamoyl-6-methylphenoxyacetone *XXXVIII
2,6-di-CH.sub.3 4-COOCH.sub.3 CH.sub.3 4-methoxycarbonyl-2,6
-dimethylphenoxyacetone XXXIX 3-OCH.sub.3 4-CONH.sub.2 CH.sub.3
4-carbamoyl-3-methoxyphenoxyaceton e *XL 2,6-di-OCH.sub.3
4-CONH.sub.2 CH.sub.3 4-carbamoyl-2,6-dimethoxyphenoxyac etone
__________________________________________________________________________
*NOTE: For Example XXXVIII, R.sup.2 and R.sup.7 are 2-CH.sub.3 and
6-CH.sub.3 respectively.
For Example XL, R.sup.2 and R.sup.7 are 2-OCH.sub.3 and 6-OCH.sub.3
respectively.
The products, isolated as the free base in each case, unless
otherwise stated, were characterized as follows.
EXAMPLE XII
1-[2-(3-carbamoyl-5-methylphenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy)
propan-2-ol
Oil, identified by spectroscopic evidence.
EXAMPLE XIII
1-[2-(2-carbamoyl-4-chlorophenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy)
-propan-2-ol
Isolated as two racemic pairs of diastereoisomers, m.p.
132.degree.-134.degree. (1) and 119.degree.-121.degree. (2),
respectively
Analysis:
isomer (1) - found: C, 61.21; H, 6.50; N, 6.84; Cl, 9.82%
isomer (2) - found: C, 61.05; H, 6.33; N, 6.85; Cl, 9.23%
Calc'd for C.sub.20 H.sub.25 N.sub.2 O.sub.4 Cl: C, 61.15; H, 6.41;
N, 7.13; Cl, 9.03%
EXAMPLE XIV
1-[2-(4-carbamoylphenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy)propan-2-
ol
m.p. 113.degree.-114.5.degree.
Analysis: Found - C, 66.44; H, 7.11; N, 7.49%
Calc'd for C.sub.20 H.sub.26 N.sub.2 O.sub.4 - C, 67.02; H, 7.31;
N, 7.82%
EXAMPLE XV
1-[2-(2-carbamoyl-5-methylphenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy)
propan-2-ol
m.p. 138.degree.
Analysis: Found - C, 67.88; H, 7.08; N, 6.80%
Calc'd for C.sub.21 H.sub.28 N.sub.2 O.sub.4 - C, 67.72; H, 7.58;
N, 7.52%
EXAMPLE XVI
1-[2-(3-carbamoylphenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy)propan-2-
ol
m.p. 116.degree.-117.degree.
Analysis: Found - C, 65.74; H, 7.52; N, 7.22%
Calc'd for C.sub.20 H.sub.26 N.sub.2 O.sub.4 - C, 65.74; H, 7.54;
N, 7.48% + 1/2 CH.sub.3 OH
(the product contained one half mole of occluded methanol.)
EXAMPLE XVII
1-[2-(2-dimethylcarbamoylphenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy)
propan-2-ol
m.p. 73.degree.-75.degree.
Analysis: Found - C, 67.97; H, 7.57; N, 7.01%
Calc'd for C.sub.22 H.sub.30 N.sub.2 O.sub.4 - C, 68.36; H, 7.82;
N, 7.25%
EXAMPLE XVIII
1-[1-(2-carbamoylphenoxymethyl)propylamino]-3-(2-methylphenoxy)propan-2-ol
m.p. 128.degree.-129.degree.
Analysis: Found - C, 67.35; H, 7.18; N, 7.19%
Calc'd for C.sub.21 H.sub.28 N.sub.2 O.sub.4 - C, 67.72; H, 7.58;
N, 7.52%
EXAMPLE XIX
1-[2-(4-nitrophenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy)propan-2-ol
m.p. 89.5.degree.
Analysis: Found - C, 62.99; H, 6.80; N, 7.44%
Calc'd for C.sub.19 H.sub.24 N.sub.2 O.sub.5 - C, 63.32; H, 6.71;
N, 7.77%
EXAMPLE XX
1-[2-(4-methoxycarbonylphenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy)pro
pan-2-ol
m.p. 75.degree.-76.degree.
Analysis: Found - C, 67.39; H, 7.48; N, 3.93%
Calc'd for C.sub.21 H.sub.27 NO.sub.5 - C, 67.54; H, 7.29; N,
3.75%
EXAMPLE XXI
1-[2-(4-cyanophenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy)propan-2-ol.
m.p. 74.degree.75.degree.
Analysis: Found - C, 70.29; H, 6.80; N, 8.17%
Calc'd for C.sub.20 H.sub.24 N.sub.2 O.sub.3 - C, 70.56; H, 7.11;
N, 8.23%
EXAMPLE XXII
1-[2-(3-trifluoromethylphenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy)pro
pan-2-ol
m.p. 75.degree.-76.degree.
Analysis: Found - C, 62.94; H, 6.19; N, 3.28%
Calc'd for C.sub.20 H.sub.24 F.sub.3 NO.sub.3 - C, 62.61; H, 6.3;
N, 3.65%
EXAMPLE XXIII
1-[2-(4-carbamoylmethylphenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy)pro
pan-2-ol
m.p. 145.degree.-6.degree.
Analysis: Found - C, 68.0; H, 7.40; N, 7.26%
Calc'd for C.sub.21 H.sub.28 N.sub.2 O.sub.4 - C, 67.7; H, 7.58; N,
7.52%
EXAMPLE XXIV
1-[2-(2-carbamoylmethylphenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy)pro
pan-2-ol
m.p. 136.degree.-138.degree.
Analysis: Found - C, 67.5; H, 7.3; N, 7.3%
Calc'd for C.sub.21 H.sub.28 N.sub.2 O.sub.4 - C, 67.7; H, 7.6; N,
7.5%
EXAMPLE XXV
1-[2-(2-n-phenylcarbamoylphenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy)
propan-2-ol
isolated as the hemi-fumarate, m.p. 176.degree.-178.degree.
Analysis: Found - C, 68.3; H, 6.7; N, 5.6%
Calc'd for C.sub.28 H.sub.32 N.sub.2 O.sub.6 - C, 68.3; H, 6.6; N,
5.7%
EXAMPLE XXVI
1-[2-(5-carbamoyl-2-methoxyphenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy
) propan-2-ol
m.p. 100.degree.-105.degree.
Analysis: Found - C, 64.5; H, 7.4; N, 6.9%
Calc'd for C.sub.21 H.sub.28 N.sub.2 O.sub.5 - C, 64.9; H, 7.3; N,
7.2%
EXAMPLE XXVII
1-[2-(4-carbamoylphenoxy)-1-methyl-ethylamino]-3-(2-phenylphenoxy)propan-2-
ol
This compound was prepared by the method of Example XII from
4-carbamoylphenoxyacetone and
DL-1-amino-3-(2-phenylphenoxy)propan-2-ol and isolated as the free
base. m.p. 158.degree.-160.degree.
Analysis: Found - C, 70.9; H, 6.9; N, 6.2%
Calc'd for C.sub.25 H.sub.28 N.sub.2 O.sub.4 - C, 71.4; H, 6.7; N,
6.7%
EXAMPLE XXVIII
1-[2-(2-n,n-dimethylcarbamoyl-4-methylphenoxy)-1-methyl-ethylamino]-3-(2-me
thylphenoxy)propan-2-ol)
Oil
Analysis: Found - C, 69.1; H, 8.0; N, 6.5%
Calc'd for C.sub.23 H.sub.32 N.sub.2 O.sub.4 - C, 69.0; H, 8.1; N,
7.0%
EXAMPLE XXIX
1-[2-(4-carbamoyl-3-methylphenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy)
propan-2-ol
m.p. 126.degree.-129.degree.
Analysis: Found - C, 67.3; H, 7.4; N, 7.1%
Calc'd for C.sub.21 H.sub.28 N.sub.2 O.sub.4 - C, 67.7; H, 7.6; N,
7.5%
EXAMPLE XXX
1-[2-(4-sulfamoyl-phenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy)propan-2
-ol
isolated as the hemi-fumarate, m.p. 185.degree.-186.degree.
Analysis: Found - C, 55.6; H, 6.2; N, 5.9%
Calc'd for C.sub.21 H.sub.28 N.sub.2 O.sub.7 S - C, 55.8; H, 6.2;
N, 6.2%
EXAMPLE XXXI
1-[2-(4-carbamoyl-2-methoxyphenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy
) propan-2-ol
m.p. 132.degree.-142.degree.
Analysis: Found - C, 65.0; H, 7.1; N, 7.0%
Calc'd for C.sub.21 H.sub.28 N.sub.2 O.sub.5 - C, 64.9; H, 7.3; N,
7.2%
EXAMPLE XXXII
1-[2-(2-carbamoyl-4-methoxyphenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy
) propan-2-ol
m.p. 109.degree.-110.degree.
Analysis: Found - C, 64.7; H, 7.1; N, 7.0%
Calc'd for C.sub.21 H.sub.28 N.sub.2 O.sub.5 - C, 64.9; H, 7.3; N,
7.2%
EXAMPLE XXXIII
1-[2-(4-carbamoyl-2-methylphenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy)
propan-2-ol
m.p. 110.degree.-113.degree.
Analysis: Found - C, 67.7; H, 7.6; N, 7.3%
Calc'd for C.sub.21 H.sub.28 N.sub.2 O.sub.4 - C, 67.7; H, 7.6; H,
7.5%
EXAMPLE XXXIV
1-[2-(3-methyl-4-nitrophenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy)prop
an-2-ol
m.p. 76.degree.-77.degree.
Analysis: Found - C, 64.4; H, 7.1; N, 7.5%
Calc'd for C.sub.20 H.sub.26 N.sub.2 O.sub.5 - C, 64.2; H, 7.0; N,
7.5%
EXAMPLE XXXV
1-[2-(4-n-aminocarbamoyl-phenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy)
propan-2-ol
This compound was prepared from the product of Example XX by
heating with hydrazine hydrate in ethanol.
m.p. 129.degree.
Analysis: Found - C, 64.2; H, 7.1; N, 11.2%
Calc'd for C.sub.20 H.sub.27 N.sub.3 O.sub.4 - C, 64.3; H, 7.3N,
11.3%
EXAMPLE XXXVI
1-[2-(5-carbamoyl-2-methylphenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy)
propan-2-ol
m.p. 122.degree.-123.degree.
Analysis: Found - C, 67.2; H, 7.1; N, 7.1%
Calc'd for C.sub.21 H.sub.28 N.sub.2 O.sub.4 - C, 67.7; H, 7.6; N,
7.5%
EXAMPLE XXXVII
1-[2-(2-carbamoyl-6-methylphenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy)
propan-2-ol
isolated as the oxalate, m.p. 170.degree.-171.5.degree.
Analysis: Found - C, 63.3; H, 7.0; N, 7.0%
Calc'd for C.sub.23 H.sub.30 N.sub.2 O.sub.8 - C, 63.3; H, 7.0; N,
6.7%
EXAMPLE XXXVIII
1-[2-(4-methoxycarbonyl-2,6-dimethylphenoxy)-1-methyl-ethylamino]-3-(2-meth
ylphenoxy)propan-2-ol
isolated as the hydrochloride, m.p. 128.degree.-130.degree.
Analysis: Found - C, 63.3; H, 7.6; N, 3.2%
Calc'd for C.sub.22 H.sub.32 NO.sub.5 Cl - C, 63.1; H, 7.4; N,
3.2%
EXAMPLE XXXIX
1-[2-(4-carbamoyl-3-methoxyphenoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy
)propan-2-ol
hydrochloride, identified by spectroscopic evidence.
m.p. 134.degree.-143.degree.
EXAMPLE XL
1-[2-(4-carbamoyl-2,6-dimethoxyphenoxy-1-methyl-ethylamino]-3-(2-methylphen
oxy)propan-2-ol
hydrochloride, identified by spectroscopic evidence.
m.p. 114.degree.-126.degree.
EXAMPLE XLI
1-[2-(4-carbamoyl-phenoxy)-1-methyl-ethylamino]-3-(1-naphthoxy)
propan-2-ol.
This compound was prepared by the method of Example XI from
4-carbamoylphenoxyacetone and DL-1-amino-3-(1-naphthoxy)
propan-2-ol and isolated as the free base, m.p.
143.degree.-144.degree..
Analysis: Found - C, 69.8; H, 6.7; N, 6.8%
Calc'd for C.sub.23 H.sub.26 N.sub.2 O.sub.4 - C, 70.0; H, 6.6; N,
7.1%
EXAMPLE XLII
1-[2-(3-carbamoyl-2-naphthoxy)-1-methyl-ethylamino]-3-(2-methylphenoxy)prop
an-2-ol
This compound was prepared by the method of Example XI from
3-carbamoyl-2-naphthoxyacetone and
DL-1-amino-3-(2-methylphenoxy)propan-2-ol and isolated as the free
base, m.p. 106.degree.-108.degree.
Analysis: Found - C, 70.21; H, 7.0; N, 6.6%
calc'd for C.sub.24 H.sub.28 N.sub.2 O.sub.4 - C, 70.56; H, 6.9; N,
6.7%
The following compounds were prepared by the method of Example IV,
from the appropriately substituted 1-phenoxy-2:3-epoxypropane and
2-(4-carbamoylphenoxy)-ethylamine, and isolated as the free base in
each case.
Analysis % Example R.sup.1 m.p. C H N
__________________________________________________________________________
XLIII 2-C.sub.6 H.sub.5 124-125.degree. 70.7 6.6 7.0 (2-phenyl)
(70.9 6.5 6.9) XLIV 3-CH.sub.3 124-126.degree. 66.1 7.2 8.4 (66.3
7.0 8.1) XLV 2-OCH.sub.3 108-112.degree. 63.2 6.9 7.9 (63.3 6.7
7.8)
__________________________________________________________________________
example xlvi
1-[2-(4-carbamoylphenoxy)ethylamino]-3-(1-naphthoxy)propan-2-ol
This compound was prepared by the method of Example IV, from
1(1-naphthoxy)-2:3-epoxypropane and 4-(2-aminoethoxy) benzamide,
and isolated as the free base, m.p. 122.degree.-123.degree..
Analysis: Found - C, 69.2; H, 6.3; N, 7.4%
calc'd for C.sub.22 H.sub.24 N.sub.2 O.sub.4 - C, 69.5; H, 6.4; N,
7.4%
EXAMPLE XLVII
1-[n-benzyl-2-(2-carbamoyl-4-methylphenoxy)-1-methyl-ethylamino]-3-(2-methy
lphenoxy)propan-2-ol
1-(2-Methylphenoxy)-2,3-epoxypropane (13.8g.),
1-(2-carbamoyl-4-methylphenoxy)-2-(benzylamino)-propane (25 g.),
ethanol (250 ml.) and water (50 ml.) were heated together under
reflux for 6 hours. The reaction mixture was evaporated and dried
in vacuo to give the free base of the desired product as a clear
oil (39g.). This oil was then dissolved in the minimum quantity of
chloroform and chromatographed on a column (80.times.3cm) packed
with silicagel, using chloroform as the eluting solvent. The first
500 ml. of eluate was collected and the solvent removed in vacuo to
give an oil which solidified after standing for two weeks. Repeated
fractional recrystallization of the solid from ethyl acetate, gave
solid products A and B, m.p. 115.degree. and 132.degree.,
respectively, which were the two racemic pairs of diastereoisomers
of the product.
Analysis:
Found for Product A: C, 72.29; H, 7.35; N, 6.20%.
for Product B: C, 72.31; H, 7.21; N, 6.06%
Calc'd for C.sub.28 H.sub.34 N.sub.2 O.sub.4 : C, 72.70; H, 7.41;
N, 6.06%
Hydrogenation of each of the products A and B of this example,
using a palladium-on-carbon catalyst, removes the N-benzyl group
and yields one of the racemic pairs of diastereoisomers of the
product of Example XI.
EXAMPLE XLVIII
The following propanolamine derivatives are prepared according to
the procedures described in Examples I, IV, V, and XI from the
appropriate starting compounds, those in which R.sub.6 is lower
alkanoyl being prepared by conventional acylation procedures from
corresponding compounds in which R.sub.6 is H:
rings A and B are both phenyl in the following table: ##SPC3##
Ring A is naphthyl and ring B is phenyl in the following table:
##SPC4##
Ring A is phenyl and ring B is naphthyl in the following table:
##SPC5##
Rings A and B are each 1-naphthyl in the following table:
##SPC6##
The activity of compounds of the invention as .beta.-adrenergic
blocking agents has been shown by their effectiveness in one or
more of the following tests: (a) blocking the action of injected
catecholamines on the isolated, perfused guinea-pig heart; (b)
suppressing the tachycardia induced by isoprenaline in the
anaesthetized rat or cat; (c) blocking the stimulating action of
isoprenaline on the adenyl cyclase enzyme present in rate heart
muscle.
In test (a), force and rate of contraction, and flow rate through
the coronary vessels, are measured. The response to standard doses
of one or more catecholamines are obtained, and the test compound
is then administered. The catecholamines and test compounds are in
all cases injected directly into the perfusing fluid immediately
before entering the coronary vessels. The catecholamine doses are
repeated and the extent of inhibition of the responses by the test
compound is measured.
In test (b), groups of five urethane-anaesthetized rats are dosed
with the test compound (2 mg./kg.) subcutaneously. Heart rates are
recorded before dosing and for thirty minutes after and the rats
are then given a subcutaneous challenge of isoprenaline (0.1
,g/kg.). The degree of isoprenaline-induced tachycardia is recorded
at fifteen minute intervals. Similarly, chloralosed cats are dosed
with the test compound (0.1 to 1.0 mg./kg.) intravenously, and the
effect of an isoprenaline challenge on heart rate is measured.
In test (c), homogenized rat heart in a standardized medium is
incubated with adenosine-5'-triphosphoric acid (ATP) labelled with
tritium, with and without isoprenaline, and the test compound is
added at various concentrations to the homogenate with the
isoprenaline. After incubation at 30.degree. C., cyclic-3',
5'-adenosinemonophosphoric acid (cyclic-AMP), containing a known
proportion of carbon-14 labelled material, is added and synthesis
of cyclic-AMP by the adenyl cyclase enzyme is stopped by raising
the temperature. Cyclic-AMP is separated and purified, and the
amount synthesized in each case by the enzyme is measured as its
tritium to carbon-14 ratio. The concentration of test compound
which gives a 50 percent inhibition of the stimulating effect of
isoprenaline on cyclic-AMP synthesis is taken as a measure of its
activity.
By these criteria, the more active compounds have been found to be
those in which R.sup.3 is a carbamoyl (including N-substituted-and
N-amino-carbamoyl, as hereinbefore described), carbamoyl-methyl (K
is 1 for (CH.sub.2).sub.K R.sup.3 -substituent), methoxycarbonyl or
cyano group in the 2- or 4-position on a phenyl group, R.sup.4 is
hydrogen or a methyl group, R.sup.5 and R.sup.6 are each hydrogen,
Y is oxygen and n is 1.
Further evaluation of these more active compounds has been carried
out by assessing their activity in suppressing isoprenaline-induced
tachycardia in dogs, the compound being administered intraveneously
and orally to conscious dogs at dose levels of 0.125 and 0.25 mg/Kg
(intravenous) and 0.5 to 4mg/Kg (orally). These tests have shown
that, of these compounds, the most active when administered orally
are those in which R.sup.1 is a methyl, methoxy or phenyl group in
the 2-position on a phenyl group and R.sup.3 is an unsubstituted
carbamoyl group or a methoxycarbonyl group, provided that, when
R.sup.3 is in the 2-position on the phenyl group, then R.sup.2 is a
methyl or methoxy group in the 4-, 5- or 6-position. Intravenous
test results in dogs confirmed relative activities found in test
(b) in rats or cats, in or test (c).
The activity of compounds of the invention as antihypertensive
agents has been shown by their effectiveness in lowering the blood
pressure of conscious hypertensive rats or dogs, using a
subcutaneous dose of 10 mg./Kg. in the rat and an oral dose of 20
mg/Kg. in the dog. Compounds having most activity in these tests
are those in which R.sup.3 is a carbamoyl or nitro group, R.sup.4
is hydrogen or a methyl group, R.sup.5 and R.sup.6 are each
hydrogen and n is 1 or 2.
The following example shows the therapeutic activity of many of the
compounds whose preparations are illustrated in the previous
examples.
EXAMPLE XLIX ##SPC7##
EXAMPLE L
The hydrochloride salt of each of the compounds of Examples
I-XLVIII is prepared by dissolving the compound as a free base in
an aqueous solution containing an equivalent amount of hydrochloric
acid and evaporating the resultant solution.
Similarly, other acid addition salts are prepared by this same
procedure corresponding to hydrobromide, hydroiodide, sulfate or
bisulphate, phosphate or acid phosphate, acetate, maleate,
fumarate, lactate, tartrate, citrate, gluconate, saccharate, and
p-toluene sulfonate by employing the appropriate acid.
EXAMPLE LI
The aldehyde condensation product of each of the compounds of
Examples I-XLVIII is prepared by reacting the compound as a free
base, in which R.sup.6 is hydrogen, with formaldehyde in ethanol
and an acid catalyst such as hydrochloric or acetic, at an elevated
temperature, and the product is then recovered after removal of the
excess water by azeotropic distillation or by means of an
entraining solvent such as benzene.
Similarly, the other aldehyde condensation products are prepared by
this same procedure corresponding to acetaldehyde, propionaldehyde,
butyraldehyde, and isobutyraldehyde.
EXAMPLE LII
The carboxylic acid ester of each of the compounds of Examples
I-XLVIII is prepared by acylating in the conventional manner the
compound as the free base with acetyl chloride and recovering the
ester.
Similarly, other carboxylic acid esters are prepared by this same
procedure corresponding to formyl chloride, propionyl chloride,
butyrylchloride, iso-butyrylchloride, benzoyl chloride, acetic
anhydride, propionic anhydride, butyric anhydride, isobutyric
anhydride, benzoic anhydride, crotonic chloride and crotonic
anhydride.
The dosage levels at which compounds of the invention should be
administered will depend on the purpose for which they are
administered, i.e. the treatment of the cardiac conditions already
mentioned or the treatment of hypertension, and also on the route
of administration, i.e. oral or parenteral, e.g. intravenous. They
will also depend on the age, body-weight and idiosyncrasies of the
individual patient, the physician in any event determining the
appropriate dosage which is most suitable for a patient. Broadly,
however, oral dosage levels for the treatment of cardiac conditions
will be in the range from 0.5 to 4 mg/Kg/day, and for the treatment
of hypertension will be in the range from 2 to 10 mg/Kg/day, these
amounts being given in up to 4 divided doses per day. Dosage levels
for intravenous administration will be about one-tenth of these in
a single dose. Thus, for an average (70Kg) adult patient,
individual oral doses in tablet or capsule form will be in the
range from 10 to 50 mg. of active compound, and intravenous doses
will be in the range from 1 to 20 mg. of active compound.
* * * * *